[HTML][HTML] mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar

…, E Al Kuwari, A Jeremijenko, AH Kaleeckal, AN Latif… - Nature medicine, 2021 - nature.com
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…

[HTML][HTML] Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar

…, A Jeremijenko, AH Kaleeckal, AN Latif… - Nature …, 2022 - nature.com
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …

[HTML][HTML] BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

…, E Al Kuwari, A Jeremijenko, AH Kaleeckal, AN Latif… - Nature medicine, 2021 - nature.com
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant,
we conducted a matched test-negative case–control study to assess the real-world …

[HTML][HTML] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

…, AA Butt, A Jeremijenko, AH Kaleeckal, AN Latif… - …, 2021 - thelancet.com
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …

Coronavirus disease 2019 disease severity in children infected with the omicron variant

…, MK Smatti, AH Kaleeckal, AN Latif… - Clinical Infectious …, 2022 - academic.oup.com
Short Summary Severe acute respiratory syndrome coronavirus 2 infection from the Omicron
variant in children/adolescents is less severe than infection from the Delta variant. Those 6 …

Assessment of the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure setting

…, A Jeremijenko, AH Kaleeckal, AN Latif… - Clinical Infectious …, 2021 - academic.oup.com
Background Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 …

Duration of immune protection of SARS-CoV-2 natural infection against reinfection

…, A Jeremijenko, AH Kaleeckal, AN Latif… - Journal of Travel …, 2022 - academic.oup.com
Background The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic hinges on virus evolution and duration of immune protection of natural infection …

Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar

…, E Al Kuwari, A Jeremijenko, AH Kaleeckal, AN Latif… - Jama, 2021 - jamanetwork.com
Importance The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly
understood. Objective To assess protection from SARS-CoV-2 breakthrough infection after …

[HTML][HTML] Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

…, A Jeremijenko, AH Kaleeckal, AN Latif… - The Lancet Infectious …, 2023 - thelancet.com
Background Long-term effectiveness of COVID-19 mRNA boosters in populations with different
previous infection histories and clinical vulnerability profiles is inadequately understood. …

Severity of illness in persons infected with the SARS-CoV-2 delta variant vs beta variant in Qatar

…, EG Concepcion, AH Kaleeckal, AN Latif… - JAMA internal …, 2022 - jamanetwork.com
Importance The Delta variant is now the predominant circulating SARS-CoV-2 strain worldwide.
Severity of illness in persons infected with the SARS-CoV-2 Delta variant compared with …